State of Alaska Department of Revenue Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN

State of Alaska Department of Revenue decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,253 shares of the biopharmaceutical company’s stock after selling 712 shares during the period. State of Alaska Department of Revenue’s holdings in Regeneron Pharmaceuticals were worth $10,825,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Marino Stram & Associates LLC increased its position in Regeneron Pharmaceuticals by 5.3% during the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 20 shares in the last quarter. CoreCap Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 9.2% during the third quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock valued at $134,000 after acquiring an additional 20 shares in the last quarter. Strait & Sound Wealth Management LLC raised its position in shares of Regeneron Pharmaceuticals by 3.5% in the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock worth $353,000 after purchasing an additional 21 shares during the last quarter. CX Institutional boosted its stake in Regeneron Pharmaceuticals by 7.9% in the 2nd quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 22 shares in the last quarter. Finally, Independence Bank of Kentucky grew its position in Regeneron Pharmaceuticals by 7.7% during the 3rd quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock valued at $173,000 after purchasing an additional 22 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Multiple analyst upgrades and higher targets — Bank of America and other firms raised ratings/targets this week, shifting consensus toward Buy and boosting investor confidence. Bank of America upgrade
• Positive Sentiment: Zacks moved REGN to a Zacks Rank #1 (Strong Buy), highlighting expectations for continued earnings outperformance. Zacks upgrade
• Positive Sentiment: Truist and other brokers raised price targets (Truist to $820), and aggregated analyst coverage (21‑analyst notes) points to a more favorable fundamental outlook — a catalyst for momentum buyers. 21‑analyst roundup
• Neutral Sentiment: Unusual options activity has picked up around REGN, signaling elevated trader interest and potential for amplified short‑term moves; direction is ambiguous. Unusual options activity
• Neutral Sentiment: Comparative analyst pieces (REGN vs peers) provide valuation context but are not immediate catalysts. REGN vs ILMN analysis
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at roughly $800 — a small dollar amount relative to market cap but sometimes triggers investor concern and short‑term profit‑taking. Insider sale SEC filing

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 8,431 shares of company stock valued at $5,733,521. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $796.55 on Friday. The business’s fifty day moving average price is $738.12 and its 200-day moving average price is $628.06. The stock has a market capitalization of $83.72 billion, a price-to-earnings ratio of 19.07, a PEG ratio of 2.17 and a beta of 0.39. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same quarter in the previous year, the company posted $12.46 earnings per share. Regeneron Pharmaceuticals’s revenue was up .9% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Truist Financial lifted their target price on shares of Regeneron Pharmaceuticals from $798.00 to $820.00 and gave the stock a “buy” rating in a report on Thursday. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Wells Fargo & Company boosted their price target on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an “equal weight” rating in a research note on Wednesday, December 10th. Finally, Canaccord Genuity Group upped their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $791.05.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.